Statins and Colorectal Cancer

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 2, 2013, Pages 109-118

  Lochhead, Paul ^a,b   Chan, Andrew T ^c,d  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adenoma; ; Chemoprevention.; Colon; ; Rectum; ; Statin;

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EZETIMIBE; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CARDIOVASCULAR RISK; COLON CANCER; COLORECTAL CANCER; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; OXIDATIVE STRESS; TREATMENT DURATION;

CHEMOPREVENTION; COLORECTAL NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84872382909     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.08.037     Document Type: Article

References (101)

1. Endo A., Tsujita Y., Kuroda M., et al. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 1977, 77:31-36.
2. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988, 319:24-33.
3. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
4. Health, United States, 2011: with special feature on socioeconomic status and health 2012, National Center for Health Statistics, Hyattsville, MD.
5. Gazzerro P., Proto M.C., Gangemi G., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 2012, 64:102-146.
6. Bonetti P.O., Lerman L.O., Napoli C., et al. Statin effects beyond lipid lowering-are they clinically relevant?. Eur Heart J 2003, 24:225-248.
7. Ma S., Ma C.C. Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily. Cytokine Growth Factor Rev 2011, 22:167-175.
8. Antonopoulos A.S., Margaritis M., Lee R., et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012, 18:1519-1530.
9. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:III39-III43.
10. Katz M.S. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2005, 2:82-89.
11. Demierre M.F., Higgins P.D., Gruber S.B., et al. Statins and cancer prevention. Nat Rev Cancer 2005, 5:930-942.
12. Oliver M.F. Might treatment of hypercholesterolaemia increase non-cardiac mortality?. Lancet 1991, 337:1529-1531.
13. Kritchevsky S.B., Kritchevsky D. Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 1992, 12:391-416.
14. Jacobs D.R., Muldoon M.F., Råstam L. Invited commentary: low blood cholesterol, nonillness mortality, and other nonatherosclerotic disease mortality: a search for causes and confounders. Am J Epidemiol 1995, 141:518-522.
15. Sharp S.J., Pocock S.J. Time trends in serum cholesterol before cancer death. Epidemiology 1997, 8:132-136.
16. Newman T.B., Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA 1996, 275:55-60.
17. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996, 335:1001-1009.
18. Coogan P.F., Rosenberg L., Palmer J.R., et al. Statin use and the risk of breast and prostate cancer. Epidemiology 2002, 13:262-267.
19. Dale K.M., Coleman C.I., Henyan N.N., et al. Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74-80.
20. Browning D.R., Martin R.M. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007, 120:833-843.
21. Bonovas S., Filioussi K., Tsavaris N., et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006, 24:4808-4817.
22. Kuoppala J., Lamminpää A., Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008, 44:2122-2132.
23. Blais L., Desgagné A., LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000, 160:2363-2368.
24. Graaf M.R., Beiderbeck A.B., Egberts A.C., et al. The risk of cancer in users of statins. J Clin Oncol 2004, 22:2388-2394.
25. Friis S., Poulsen A.H., Johnsen S.P., et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005, 114:643-647.
26. Poynter J.N., Gruber S.B., Higgins P.D., et al. Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184-2192.
27. Hoffmeister M., Chang-Claude J., Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 2007, 121:1325-1330.
28. Farwell W.R., Scranton R.E., Lawler E.V., et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008, 100:134-139.
29. Hachem C., Morgan R., Johnson M., et al. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol 2009, 104:1241-1248.
30. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011, 11:761-774.
31. Rathinam R., Berrier A., Alahari S.K. Role of rho GTPases and their regulators in cancer progression. Front Biosci 2011, 16:2561-2571.
32. Duncan R.E., El-Sohemy A., Archer M.C. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem 2004, 279:33079-33084.
33. Clendening J.W., Penn L.Z. Targeting tumor cell metabolism with statins. Oncogene 2012 Feb 6, Epub ahead of print.
34. Davignon J., Jacob R.F., Mason R.P. The antioxidant effects of statins. Coron Artery Dis 2004, 15:251-258.
35. Weitz-Schmidt G., Welzenbach K., Brinkmann V., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001, 7:687-692.
36. Wagner B.J., Löb S., Lindau D., et al. Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. Int J Oncol 2011, 39:1593-1600.
37. Malicki S., Winiarski M., Matlok M., et al. IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. J Physiol Pharmacol 2009, 60:141-146.
38. Smaldone C., Brugaletta S., Pazzano V., et al. Immunomodulator activity of 3-hydroxy-3-methylglutaryl-CoA inhibitors. Cardiovasc Hematol Agents Med Chem 2009, 7:279-294.
39. Elewa H.F., El-Remessy A.B., Somanath P.R., et al. Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy 2010, 30:169-176.
40. Agarwal B., Bhendwal S., Halmos B., et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999, 5:2223-2229.
41. Wächtershäuser A., Akoglu B., Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line caco-2. Carcinogenesis 2001, 22:1061-1067.
42. Qi X.F., Kim D.H., Yoon Y.S., et al. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett 2010, 199:277-287.
43. Yang P.M., Liu Y.L., Lin Y.C., et al. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res 2010, 70:7699-7709.
44. Guruswamy S., Rao C.V. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: implications for colon cancer prevention. Int J Oncol 2009, 35:1037-1043.
45. Kaneko R., Tsuji N., Asanuma K., et al. Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem 2007, 282:19273-19281.
46. Kodach L.L., Bleuming S.A., Peppelenbosch M.P., et al. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 2007, 133:1272-1281.
47. Suh N., Reddy B.S., DeCastro A., et al. Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats. Cancer Prev Res (Phila) 2011, 4:1895-1902.
48. Yasuda Y., Shimizu M., Shirakami Y., et al. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010, 101:1701-1707.
49. Teraoka N., Mutoh M., Takasu S., et al. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res (Phila) 2011, 4:445-453.
50. Swamy M.V., Patlolla J.M., Steele V.E., et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006, 66:7370-7377.
51. Lee J., Lee I., Han B., et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 2011, 103:674-688.
52. Kodach L.L., Jacobs R.J., Voorneveld P.W., et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell "stemness" via the bone morphogenetic protein pathway. Gut 2011, 60:1544-1553.
53. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
54. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002, 359:1379-1387. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease).
55. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
56. Strandberg T.E., Pyorala K., Cook T.J., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2003, 364:771-777.
57. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial. BMC Med 2005, 3:6. Heart Protection Study Collaborative Group.
58. Ford I., Murray H., Packard C.J., et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007, 357:1477-1486.
59. Hsia J., MacFadyen J.G., Monyak J., et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011, 57:1666-1675.
60. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
61. Bonovas S., Filioussi K., Flordellis C.S., et al. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007, 25:3462-3468.
62. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
63. Emberson J.R., Kearney P.M., et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012, 7:e29849. Cholesterol Treatment Trialists' (CTT) Collaboration.
64. Bulbulia R., Bowman L., et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011, 378:2013-2020. Heart Protection Study Collaborative Group.
65. Lipkin S.M., Chao E.C., Moreno V., et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) 2010, 3:597-603.
66. Kaye J.A., Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004, 90:635-637.
67. Vinogradova Y., Hippisley-Cox J., Coupland C., et al. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007, 133:393-402.
68. Coogan P.F., Rosenberg L., Strom B.L. Statin use and the risk of 10 cancers. Epidemiology 2007, 18:213-219.
69. Coogan P.F., Smith J., Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007, 99:32-40.
70. Yang Y.X., Hennessy S., Propert K., et al. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 2008, 17:869-876.
71. Boudreau D.M., Koehler E., Rulyak S.J., et al. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:3076-3080.
72. Shadman M., Newcomb P.A., Hampton J.M., et al. Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World J Gastroenterol 2009, 15:2336-2339.
73. Robertson D.J., Riis A.H., Friis S., et al. Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer. Clin Gastroenterol Hepatol 2010, 8:1056-1061.
74. Vinogradova Y., Coupland C., Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2011, 11:409.
75. Cheng M.H., Chiu H.F., Ho S.C., et al. Statin use and the risk of colorectal cancer: a population-based case-control study. World J Gastroenterol 2011, 17:5197-5202.
76. Lee J.E., Baba Y., Ng K., et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) 2011, 4:1808-1815.
77. Simon M.S., Rosenberg C.A., Rodabough R.J., et al. Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol 2012, 22:17-27.
78. Jacobs E.J., Rodriguez C., Brady K.A., et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006, 98:69-72.
79. Setoguchi S., Glynn R.J., Avorn J., et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007, 115:27-33.
80. Friedman G.D., Flick E.D., Udaltsova N., et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008, 17:27-36.
81. Singh H., Mahmud S.M., Turner D., et al. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009, 104:3015-3023.
82. Flick E.D., Habel L.A., Chan K.A., et al. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs 2009, 69:1445-1457.
83. Haukka J., Sankila R., Klaukka T., et al. Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010, 126:279-284.
84. Jacobs E.J., Newton C.C., Thun M.J., et al. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011, 71:1763-1771.
85. Taylor M.L., Wells B.J., Smolak M.J. Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 2008, 17:259-268.
86. Thomsen R.W., Johnsen S.P., Olesen A.V., et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005, 60:534-542.
87. Siddiqui A.A., Nazario H., Mahgoub A., et al. The long-term use of statins is associated with a decreased incidence of adenomatous colon polyps. Digestion 2009, 79:17-22.
88. Siddiqui A., Nazario H.E., Patel M., et al. Reduction in low-density lipoprotein cholesterol levels during statin therapy is associated with a reduced incidence of advanced colon polyps. Am J Med Sci 2009, 338:378-381.
89. Parker-Ray N., Barakat J., Roy P.K., et al. Statin use does not prevent recurrent adenomatous polyp formation in a VA population. Indian J Gastroenterol 2010, 29:106-111.
90. Wei J.T., Mott L.A., Baron J.A., et al. Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2005, 14:1026-1027.
91. Bertagnolli M.M., Hsu M., Hawk E.T., et al. Statin use and colorectal adenoma risk: results from the Adenoma Prevention With Celecoxib trial. Cancer Prev Res (Phila) 2010, 3:588-596.
92. Siddiqui A.A., Nazario H., Mahgoub A., et al. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci 2009, 54:1307-1311.
93. Ng K., Ogino S., Meyerhardt J.A., et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 2011, 103:1540-1551.
94. Limburg P.J., Mahoney M.R., Ziegler K.L., et al. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res (Phila) 2011, 4:259-269.
95. Lee J., Jung K.H., Park Y.S., et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol 2009, 64:657-663.
96. ClinicalTrials.gov, A service of the U.S. National Institutes of Health Accessed July 16, 2012. http://www.clinicaltrialsgov.
97. National Surgical Adjuvant Breast and Bowel Project: Phase III Randomized Study of Adjuvant Rosuvastatin in Patients With Resected Stage I or II Colon Cancer Clinical Trials (PDQ®), National Cancer Institute, Accessed July 16, 2012. http://Cancer.gov/clinicaltrials/NSABP-P-5.
98. Zhou P., Cheng S.W., Yang R., et al. Combination chemoprevention: future direction of colorectal cancer prevention. Eur J Cancer Prev 2012, 21:231-240.
99. Xiao H., Zhang Q., Lin Y., et al. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 2008, 122:2115-2124.
100. Reddy B.S., Wang C.X., Kong A.N., et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006, 66:4542-4546.
101. Hennekens C.H., Buring J.E., Manson J.E., et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996, 334:1145-1149.